Abstract
Despite extensive research into stroke pathology, there have not been any major recent advancements in stroke therapeutics. Animal models of cerebral ischemia and clinical data have been used to investigate the progressive neural injury that occurs after an initial ischemic insult. This has lead researchers to focus more on the peripheral immune response that is generated as a result of cerebral ischemia. The therapies that have been developed as a result of this research thus far have proven ineffective in clinical trials. The failure of these therapeutics in clinical trials is thought to be due to the broad immunosuppression elicited as a result of the treatments and the cerebral ischemia itself. Emerging evidence indicates a more selective modulation of the immune system following stroke could be beneficial. The spleen has been shown to exacerbate neural injury following experimental stroke and would provide a strong therapeutic target. Selecting facets of the immune system to target would allow the protective and regenerative properties of the immune response to remain intact while blunting the pro-inflammatory response generated towards the injured brain.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 543-553 |
| Number of pages | 11 |
| Journal | Translational Stroke Research |
| Volume | 5 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2014 |
| Externally published | Yes |
Keywords
- Interferon gamma
- Spleen
- Stroke
- T cells
ASJC Scopus subject areas
- General Neuroscience
- Clinical Neurology
- Cardiology and Cardiovascular Medicine